Increased choline kinase activity in human breast carcinomas: clinical evidence for a potential novel antitumor strategy.
about
Differential role of human choline kinase alpha and beta enzymes in lipid metabolism: implications in cancer onset and treatmentRegulation of Akt(ser473) phosphorylation by choline kinase in breast carcinoma cellsCholine and betaine intake and risk of breast cancer among post-menopausal womenDietary choline and betaine and the risk of distal colorectal adenoma in womenCholine Metabolism Alteration: A Focus on Ovarian CancerThe human plasma lipidomeCholine metabolism-based molecular diagnosis of cancer: an updateThe E2F2 transcription factor sustains hepatic glycerophospholipid homeostasis in miceHuman Choline Kinase-α Promotes Hepatitis C Virus RNA Replication through Modulation of Membranous Viral Replication Complex FormationCholine kinase and its functionHighly specific antibodies for co-detection of human choline kinase α1 and α2 isoformsDownregulation of Choline Kinase-Alpha Enhances Autophagy in Tamoxifen-Resistant Breast Cancer CellsMetformin Decouples Phospholipid Metabolism in Breast Cancer CellsFunctional interactions between Choline kinase α, epidermal growth factor receptor and c-Src in breast cancer cell proliferationCholine-releasing glycerophosphodiesterase EDI3 drives tumor cell migration and metastasisA new family of choline kinase inhibitors with antiproliferative and antitumor activity derived from natural products.Non-invasive in vivo imaging of early metabolic tumor response to therapies targeting choline metabolism.The response of RIF-1 fibrosarcomas to the vascular-disrupting agent ZD6126 assessed by in vivo and ex vivo 1H magnetic resonance spectroscopy.Restricted water diffusibility as measured by diffusion-weighted MR imaging and choline uptake in (11)C-choline PET/CT are correlated in pelvic lymph nodes in patients with prostate cancer.Molecular Imaging of Prostate CancerPhospholipase D1 and choline kinase-α are interactive targets in breast cancer.Activation of phosphatidylcholine cycle enzymes in human epithelial ovarian cancer cells.Mycobacterial heat shock protein 65 mediated metabolic shift in decidualization of human endometrial stromal cellsInvestigation of discriminant metabolites in tamoxifen-resistant and choline kinase-alpha-downregulated breast cancer cells using 1H-nuclear magnetic resonance spectroscopy.Magnetic resonance spectroscopy in metabolic and molecular imaging and diagnosis of cancer1H/31P polarization transfer at 9.4 Tesla for improved specificity of detecting phosphomonoesters and phosphodiesters in breast tumor models.Glycerophosphodiester phosphodiesterase domain containing 5 (GDPD5) expression correlates with malignant choline phospholipid metabolite profiles in human breast cancerCharacterization of breast cancers and therapy response by MRS and quantitative gene expression profiling in the choline pathway.Nanoplex delivery of siRNA and prodrug enzyme for multimodality image-guided molecular pathway targeted cancer therapyDirect inhibition of choline kinase by a near-infrared fluorescent carbocyanineCholine kinase alpha and hexokinase-2 protein expression in hepatocellular carcinoma: association with survival.HR-MAS MR spectroscopy of breast cancer tissue obtained with core needle biopsy: correlation with prognostic factors.Early embryonic lethality caused by disruption of the gene for choline kinase alpha, the first enzyme in phosphatidylcholine biosynthesis.Combined 5-FU and ChoKα inhibitors as a new alternative therapy of colorectal cancer: evidence in human tumor-derived cell lines and mouse xenografts.Clinical characteristics and biomarkers of breast cancer associated with choline concentration measured by 1H MRS.Choline kinase overexpression increases invasiveness and drug resistance of human breast cancer cellsMechanisms of indomethacin-induced alterations in the choline phospholipid metabolism of breast cancer cells.Molecular and functional imaging of invasion and metastasis: windows into the metastatic cascade.A novel small molecule antagonist of choline kinase-α that simultaneously suppresses MAPK and PI3K/AKT signalingCholine metabolism in malignant transformation.
P2860
Q24317541-50BEB5F9-765B-4FBB-B569-4624D5E50CEEQ24646815-9627E3A1-C0F4-486B-A98C-50D81975EA93Q24647098-2FE79FFA-F4BD-48A5-866B-2BD5074407D1Q24649145-10ED9CDF-9EF5-4179-B344-6C96F153345BQ26742116-7E5E44E6-C6F4-4112-9977-17F26661B04FQ26830940-87F8EFE2-D7EC-4727-9EED-A2D12455FAE4Q27024079-34A891DE-C5FC-4574-A4CE-4A6386FBAE42Q27329136-D54CA891-3156-469D-BC02-EEEBAD8BD205Q27468561-840FD6FB-4C9D-4B9E-B995-40AD46B72765Q28288614-C36B9BED-5270-42CC-A830-A5CF8D1E4669Q28475590-FF845146-A13A-43F3-8322-141D83949974Q28550472-35943E02-99E5-4928-9DEE-3BAED40ACF5CQ28550634-B89CC07E-E34B-4BA8-96CC-380C56812DC9Q30424954-18E643BA-BD68-4E3B-8F0C-53F00DC8B35CQ30514230-6061B0F2-1D79-49F8-9B91-FD99830EC401Q30874197-52A81E12-D489-4C7F-BD47-774AD05F2AFFQ31027315-52EE90AC-A67A-49D3-BAAF-8DC6E0E3B41CQ31049713-36FB9782-1DA1-4639-991E-41889733FC50Q33583831-CF55EFE4-1485-4425-B080-FF18183D10BDQ33620520-A7C2F85F-4568-44A6-91F0-962C790B2CDBQ33631482-FEE88708-4492-4B4A-AA2C-53DDCADDC7D4Q33699139-00B9E88D-2AF4-46C6-ACDA-DF1F7BCEAAEAQ33822437-9210BBB3-9721-4404-8384-B59D86756B96Q33828887-5E371B9A-08CB-4AF3-B4DF-799B5F576F67Q33881902-2D55B4F1-AB55-4215-9F0E-5532A837854FQ33921319-96480496-D4EE-42D4-B457-CCF1F0C7B6FAQ34020037-AE4F6CFF-84BC-45C4-A110-1DC27CC92661Q34035237-BF245185-31D2-42FE-9020-0D7E94F49275Q34348175-AA2A0DA0-D21F-400E-B4FA-341CF95FC4C4Q34407085-5DB5E955-66A7-4486-8C07-83B70E76CDACQ34447257-8B310C3C-BFCB-4C32-857C-5A9954A03186Q34525558-2D284067-82C3-419C-A994-0627464EDABCQ34552969-05FE41FE-8AB5-4C41-BA98-D0D1B2FF7DCDQ34769536-AA9DF7F2-1B57-4097-90F1-B43CC3ACC360Q34788629-4FD6D207-552F-405B-A8CA-6A940E71A2BEQ35046962-F3BA43DB-4A0E-4D3C-A14C-E4A4C69A2346Q35060329-1ED68B72-7A70-4CA0-A122-D96C32536FADQ35064453-46F91FD2-47CE-42B4-8C37-3E974D1947B8Q35106366-F758CB3D-F691-4493-A504-1173246FEC86Q35112040-D5608F22-32F1-447A-94DF-C0CA3A50AD5E
P2860
Increased choline kinase activity in human breast carcinomas: clinical evidence for a potential novel antitumor strategy.
description
2002 nî lūn-bûn
@nan
2002 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Increased choline kinase activ ...... tial novel antitumor strategy.
@ast
Increased choline kinase activ ...... tial novel antitumor strategy.
@en
Increased choline kinase activ ...... tial novel antitumor strategy.
@nl
type
label
Increased choline kinase activ ...... tial novel antitumor strategy.
@ast
Increased choline kinase activ ...... tial novel antitumor strategy.
@en
Increased choline kinase activ ...... tial novel antitumor strategy.
@nl
prefLabel
Increased choline kinase activ ...... tial novel antitumor strategy.
@ast
Increased choline kinase activ ...... tial novel antitumor strategy.
@en
Increased choline kinase activ ...... tial novel antitumor strategy.
@nl
P2093
P2860
P356
P1433
P1476
Increased choline kinase activ ...... tial novel antitumor strategy.
@en
P2093
Ana Ramírez de Molina
Félix Bonilla
Javier Silva
José Javier Sánchez
José María Silva
Juan Carlos Lacal
Maria Angeles Ramos
Ruth Gutiérrez
P2860
P2888
P304
P356
10.1038/SJ.ONC.1205556
P407
P577
2002-06-01T00:00:00Z
P5875
P6179
1013092478